Colorectal Cancer: Incidence, Screening, and Treatment | Market Intelligence

Description

List of Tables

Japan carries one of the heaviest colorectal cancer burdens in the developed world. It is now the country's most frequently diagnosed malignancy, a position earned through decades of dietary westernization, an aging population, and a screening system that has never reached the participation levels achieved in Northern Europe or the United States. For companies operating in gastrointestinal oncology, diagnostics, or population health, Japan is simultaneously a large established market and a case study in how much room for improvement remains in a high-income health system.

The tensions are well defined. Screening participation hovers far below policy targets, split between a municipal program built on fecal immunochemical testing and an employer-based channel that follows different rules and incentives. Once cancer is found, the treatment landscape is being reshaped from several directions at once: immunotherapy for mismatch-repair-deficient tumors, targeted agents for KRAS, BRAF, and HER2 alterations, and the arrival of blood-based minimal residual disease testing that promises to change how adjuvant chemotherapy decisions are made after surgery. Japan's own GALAXY and CIRCULATE-Japan evidence programs have made the country a proving ground for ctDNA-guided treatment, even as reimbursement and clinical-guideline integration remain unsettled. Prevention is the third contested front, with H. pylori-style population strategies absent for the colon and debate continuing over the right balance between FIT-based screening and colonoscopy capacity.

This report organizes the colorectal cancer landscape in Japan from prevention through survivorship. It begins with epidemiology and risk-factor trends, then examines the screening system's structure, participation economics, and the technologies competing to raise uptake. The treatment chapters map the approved drug landscape line by line, the biomarker-testing infrastructure that gates targeted therapy, the surgical and endoscopic treatment base, and the emerging role of MRD testing in adjuvant decision-making. A comparative chapter places Japan against the United States, Europe, and China on screening design and treatment access.

The report serves gastrointestinal oncology business-development teams assessing Japan entry or licensing, screening and diagnostics companies evaluating channel strategy, and investors tracking the companies - domestic and foreign - that compete across the care pathway. It answers where the system creates commercial openings and where structural constraints will bind.

Scope and Coverage: The report covers colorectal cancer epidemiology, screening programs, diagnostics, and treatment in Japan, with comparative reference points from the United States, Europe, and China. It spans prevention, early detection, biomarker testing, systemic and surgical treatment, and post-treatment surveillance.

Report Highlights:

Colorectal cancer incidence, mortality, and stage distribution across Japan's prefectures and age bands
Structure and participation economics of the municipal and employer screening channels
Approved systemic therapies mapped by line of treatment and biomarker-defined subgroup
The GALAXY and CIRCULATE-Japan ctDNA evidence base and its implications for adjuvant practice
Colonoscopy capacity, endoscopic resection practice, and AI-assisted detection adoption
Company profiles spanning screening, diagnostics, and therapeutics across the care pathway

Product Code: JPH-039

Table of Content

1. Executive Summary

2. Colorectal Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Natera (US) - Signatera tumor-informed ctDNA MRD test, first MRD assay approved by PMDA (2026) for CRC adjuvant decisions. Guardant Health (US) - Reveal tissue-free MRD assay and Shield blood-based CRC screening test (FDA approval 2024). Exact Sciences (US) - Cologuard stool-DNA screening and Oncodetect MRD; Japan screening rights historically licensed to Eiken/Otsuka. Merck & Co (US) - Keytruda in first-line MSI-H/dMMR metastatic CRC. Bristol Myers Squibb (US) - Opdivo+Yervoy in MSI-H/dMMR metastatic CRC. Sysmex (JP) - HISCL immunoassay and Inostics OncoBEAM ctDNA assays in the CRC biomarker menu. Eiken Chemical (JP) - OC-Sensor FIT kits used in Japan's national colorectal screening program. Olympus (JP) - colonoscope installed base and EVIS X1 platform underpinning colonoscopy capacity. Fujifilm (JP) - endoscopy systems and CAD EYE AI polyp detection. Taiho Pharmaceutical (JP) - Lonsurf (trifluridine/tipiracil), Japan-originated later-line CRC therapy. Bayer (DE) - Stivarga (regorafenib) and Fruzaqla (fruquintinib) later-line CRC options. Pfizer (US) - Braftovi+Erbitux regimen for BRAF-mutant CRC. Daiichi Sankyo (JP) - Enhertu in HER2-expressing metastatic CRC. Burning Rock (CN) - tumor-informed MRD and multi-cancer early detection portfolio in China.

Product Code: JPH-039

List of Tables

Table 1. Colorectal cancer incidence and mortality statistics by prefecture and age band
Table 2. Age-standardized incidence trend for colon versus rectal cancer in Japan
Table 3. Stage distribution at diagnosis by detection route (screening versus symptomatic)
Table 4. Lifetime cumulative risk of colorectal cancer in Japan compared with the US and EU5
Table 5. Prefectural variation in colorectal cancer mortality rates
Table 6. Risk-factor prevalence in Japan: dietary patterns, obesity, smoking, and alcohol intake
Table 7. Hereditary colorectal cancer syndromes: Lynch syndrome and FAP registry status in Japan
Table 8. Colorectal cancer screening program design: municipal versus employer channels
Table 9. FIT-based screening participation rates by prefecture and fiscal year
Table 10. Employer-based health check coverage of colorectal screening items
Table 11. Screening interval and cutoff policies for fecal immunochemical testing in Japan
Table 12. Diagnostic follow-up completion rates after positive FIT results
Table 13. Comparison of Japan screening parameters with USPSTF and European program designs
Table 14. Cologuard and Eiken/Otsuka stool-DNA licensing history in Japan
Table 15. Guardant Shield and blood-based screening test status in the Japanese market
Table 16. Colonoscopy capacity: endoscopist workforce and facility distribution by region
Table 17. Endoscopic submucosal dissection and EMR practice patterns for early lesions
Table 18. AI-assisted polyp detection systems approved for Japanese endoscopy (CAD EYE, EndoBRAIN)
Table 19. Surgical treatment volumes for colorectal cancer by procedure type
Table 20. Robotic and laparoscopic colectomy adoption under NHI reimbursement
Table 21. Japan Clinical Oncology Group trial portfolio in colorectal cancer
Table 22. Japanese Society for Cancer of the Colon and Rectum guideline structure and update cycle
Table 23. Biomarker testing rates for RAS, BRAF, MSI, and HER2 in metastatic disease
Table 24. Approved first-line regimens for metastatic colorectal cancer in Japan
Table 25. Bevacizumab and anti-EGFR antibody positioning in Japanese first-line practice
Table 26. Braftovi plus cetuximab regimen status for BRAF-mutant disease in Japan
Table 27. Lumakras and KRAS G12C inhibitor development status in Japan
Table 28. Enhertu development status for HER2-positive colorectal cancer in Japan
Table 29. Keytruda and Opdivo indications for MSI-high colorectal cancer in Japan
Table 30. Regorafenib, trifluridine/tipiracil, and fruquintinib in later-line treatment
Table 31. Fruquintinib Japan approval status following the FRESCO-2 program
Table 32. GALAXY study design and ctDNA clearance endpoints in CIRCULATE-Japan
Table 33. CIRCULATE-Japan VEGA, ALTAIR, and related trial schema for MRD-guided adjuvant therapy
Table 34. Signatera PMDA approval pathway and intended-use population (2026)
Table 35. Guardant Reveal and Oncodetect MRD assay status relative to Japan
Table 36. NHI reimbursement status for ctDNA MRD testing after colorectal surgery
Table 37. Adjuvant chemotherapy guideline criteria for stage II and III colon cancer in Japan
Table 38. OXALIS and ACTS-CC trial influence on Japanese adjuvant practice
Table 39. Ostomy care and stoma appliance market structure in Japan
Table 40. Colorectal cancer treatment cost structure under NHI and high-cost benefit caps
Table 41. National Cancer Center and designated cancer hospital network for colorectal care
Table 42. Clinical trial enrollment infrastructure for colorectal oncology in Japan
Table 43. China colorectal screening and treatment comparison: NRDL coverage of key agents
Table 44. EU5 colorectal screening program designs and participation benchmarks
Table 45. US colorectal screening landscape after the age-45 guideline shift
Table 46. Company profiles: Eiken Chemical, Otsuka, and domestic screening suppliers
Table 47. Company profiles: Natera, Guardant Health, and Exact Sciences in the Japan MRD market
Table 48. Company profiles: Merck, Bristol Myers Squibb, Roche, and Taiho in Japanese CRC therapeutics
Table 49. Pipeline overview: colorectal trials with Japanese site participation registered through 2026
Table 50. Prefectural screening promotion programs and subsidy mechanisms

List of Figures

Figure 1. Colorectal cancer incidence trend in Japan by sex, historical series
Figure 2. Colorectal cancer mortality trend in Japan by sex, historical series
Figure 3. Age-specific incidence curves for colon and rectal cancer in Japan
Figure 4. Stage distribution at diagnosis: screening-detected versus symptomatic cases
Figure 5. Map of prefectural variation in screening participation
Figure 6. Municipal versus employer screening channel structure and flows
Figure 7. FIT screening pathway from invitation to colonoscopy confirmation
Figure 8. Drop-off at each step of the screening cascade in Japan
Figure 9. International comparison of screening participation: Japan, US, EU5, China
Figure 10. Colonoscopy volume trend in Japan by fiscal year
Figure 11. Distribution of endoscopy facilities capable of ESD by region
Figure 12. Biomarker prevalence in Japanese metastatic colorectal cancer: RAS, BRAF, MSI, HER2
Figure 13. Treatment sequencing map for metastatic colorectal cancer in Japan
Figure 14. First-line regimen selection logic under Japanese guidelines
Figure 15. Timeline of colorectal drug approvals in Japan by class
Figure 16. Anti-EGFR versus anti-VEGF first-line positioning in Japan versus Western practice
Figure 17. KRAS G12C inhibitor development pipeline relevant to Japan
Figure 18. Immunotherapy indications in colorectal cancer by biomarker subgroup
Figure 19. GALAXY study patient flow and ctDNA measurement schedule
Figure 20. CIRCULATE-Japan platform structure linking VEGA and ALTAIR trials
Figure 21. MRD-guided adjuvant decision pathway after curative surgery
Figure 22. Signatera test workflow from tumor sequencing to surveillance draws
Figure 23. Reimbursement decision timeline for ctDNA MRD testing in Japan
Figure 24. Stage III adjuvant chemotherapy regimen use patterns in Japan
Figure 25. Five-year survival by stage in Japan compared with US SEER and EUROCARE
Figure 26. Colorectal cancer screening guideline evolution in Japan
Figure 27. Stoma creation rates and ostomy care pathway in Japan
Figure 28. Distribution of designated cancer care hospitals treating colorectal cancer
Figure 29. Patient flow from primary screening to tertiary cancer centers
Figure 30. Employer health-check contract structure for colorectal screening items
Figure 31. Prefectural disparities in diagnostic follow-up after positive FIT
Figure 32. Trend in early-stage detection share attributable to screening
Figure 33. Robotic surgery adoption curve for colorectal resection in Japan
Figure 34. Laparoscopic versus open surgery mix by hospital size
Figure 35. Japan CRC drug market structure by therapeutic class
Figure 36. Company positioning map across screening, diagnostics, and therapeutics
Figure 37. China colorectal care pathway comparison with Japan
Figure 38. EU5 screening program architectures compared with Japan's dual channel
Figure 39. US multi-target stool DNA and blood-test screening adoption trajectory
Figure 40. Blood-based screening test performance study designs relevant to Japan entry
Figure 41. Post-polypectomy surveillance interval guidelines in Japan versus the US
Figure 42. Young-onset colorectal cancer incidence trend in Japan
Figure 43. Screening promotion campaign models at municipal level
Figure 44. Digital reminder and navigation interventions tested in Japanese screening programs
Figure 45. Colorectal cancer clinical trial site network across Japanese regions
Figure 46. Endoscopic AI detection workflow in Japanese colonoscopy practice
Figure 47. Adjuvant treatment decision framework integrating MRD status
Figure 48. Survivorship care and surveillance imaging practice in Japan
Figure 49. Research and policy agenda for closing the screening participation gap
Figure 50. Lynch syndrome testing and cascade-screening pathway in Japan

Colorectal Cancer: Incidence, Screening, and Treatment | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Colorectal Cancer: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures